Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Rare Cancer Treatments and the Power of Checkpoint Inhibitors Among Hot Topics at ASCO

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.

Read More »

Without older subjects, cancer drug trials rely on atypical patients

Cancer drug study patients tend to be younger than most people with the disease in the general population.

Read More »

Five-Year Survival Observed In Longest Follow-Up Of Advanced Melanoma Patients Treated With Opdivo-Yervoy Combination

Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.

Read More »

Weekend Highlights from 2019 ASCO Annual Meeting

There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.

Read More »

IQVIA Global Oncology Trends: An Interview with Murray Aitken

The IQVIA Institute for Human Data Science is releasing the 2019 “Global Oncology Trends” report simultaneously with the American Society of Clinical Oncology (ASCO) Meeting.

Read More »

Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.

Read More »

Astellas Takes a $387 Million+ Loss as It Shuts Down SoCal’s Agensys

Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.

Read More »

Bristol-Myers Squibb Loses $4.3 Billion in Market Value After ASCO Update

In the eyes of investors, Bristol-Myers Squibb has not really recovered from bad news in August 2016 of its clinical trial of Opdivo (nivolumab) as monotherapy in non-small cell lung cancer. Although the company had quite a bit of good news at the June 2017 ASCO meeting, investors still seem leery.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom